Drug management of oxidation-reduction state of the body in respiratory tract diseases (part 1)

A.E. Abaturov, A.P. Volosovets, T.P. Borysova


The review of the literature presents the classification of antioxidant drugs. Modern data are presented on the inhibitors of NOX activity such as natural, synthetic (non-selective and selective), renin-angiotensin-aldosterone system blo­cking drugs and statins. The effect of statins on the oxidation-reduction status, inflammation and remodeling processes of the bronchial tree in chronic obstructive pulmonary disease is shown.


diseases of the respiratory system; antioxidant system; drug management; review


Drinitsina SV, Zateyshchikov DA. Antioxidant properties of statins. Kardiologiia. 2005;45(4):65. (in Russian).

Shenoy V, Qi Y, Katovich MJ, Raizada MK. ACE2, a promising therapeutic target for pulmonary hypertension. Curr Opin Pharmacol. 2011 Apr;11(2):150-5. doi: 10.1016/j.coph.2010.12.002.

Ahmad T, Mabalirajan U, Ghosh B, Agrawal A. Altered asymmetric dimethyl arginine metabolism in allergically inflamed mouse lungs. Am J Respir Cell Mol Biol. 2010 Jan;42(1):3-8. doi: 10.1165/rcmb.2009-0137RC.

Uhal BD, Dang MT, Li X, Abdul-Hafez A. Angiotensinogen gene transcription in pulmonary fibrosis. Int J Pept. 2012;2012:875910. doi: 10.1155/2012/875910.

Mandal S, Satish Y, Sunita Y, Nema RK. Antioxidants: A Review. J Chem Pharmac Research. 2009;1(1):102-104.

Silva D, Couto M, Delgado L, Moreira A. A systematic review of statin efficacy in asthma. J Asthma. 2012 Nov;49(9):885-94. doi: 10.3109/02770903.2012.721433.

Carnesecchi S, Pache JC, Barazzone-Argiroffo C. NOX enzymes: potential target for the treatment of acute lung injury. Cell Mol Life Sci. 2012 Jul;69(14):2373-85. doi: 10.1007/s00018-012-1013-6.

Miguel-Carrasco JL, Zambrano S, Blanca AJ, Mate A, Vázquez CM. Captopril reduces cardiac inflammatory markers in spontaneously hypertensive rats by inactivation of NF-kB. J Inflamm (Lond). 2010 May 12;7:21. doi: 10.1186/1476-9255-7-21.

Wassmann S, Laufs U, Müller K, et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol. 2002 Feb 1;22(2):300-5. PMID:11834532.

Kim WC, Berquist BR, Chohan M, Uy C, Wilson DM 3rd, Lee CH. Characterization of the endoribonuclease active site of human apurinic/apyrimidinic endonuclease 1. J Mol Biol. 2011 Sep 2;411(5):960-71. doi: 10.1016/j.jmb.2011.06.050.

Wind S, Beuerlein K, Eucker T, Müller H, Scheurer P, Armitage ME, Ho H, Schmidt HH, Wingler K. Comparative pharmacology of chemically distinct NADPH oxidase inhibitors. Br J Pharmacol. 2010 Oct;161(4):885-98. doi: 10.1111/j.1476-5381.2010.00920.x.

Day BJ. Antioxidants as potential therapeutics for lung fibrosis. Antioxid Redox Signal. 2008 Feb;10(2):355-70. doi:10.1089/ars.2007.1916.

Datta A, Scotton CJ, Chambers RC. Novel therapeutic approaches for pulmonary fibrosis. Br J Pharmacol. 2011 May;163(1):141-72. doi: 10.1111/j.1476-5381.2011.01247.x.

de Andrade JA, Thannickal VJ. Innovative approaches to the therapy of fibrosis. Curr Opin Rheumatol. 2009 Nov;21(6):649-55. doi: 10.1097/BOR.0b013e328330da9b.

Osaki T, Uchida Y, Hirayama J, Nishina H. Diphenyleneiodonium chloride, an inhibitor of reduced nicotinamide adenine dinucleotide phosphate oxidase, suppresses light-dependent induction of clock and DNA repair genes in zebrafish. Biol Pharm Bull. 2011;34(8):1343-7. PMID:21804230.

Lokhandwala T, West-Strum D, Banahan BF, Bentley JP, Yang Y. Do statins improve outcomes in patients with asthma on inhaled corticosteroid therapy? A retrospective cohort analysis. BMJ Open. 2012 May 22;2(3). pii: e001279. doi: 10.1136/bmjopen-2012-001279.

Dobler CC, Wong KK, Marks GB. Associations between statins and COPD: a systematic review. BMC Pulm Med. 2009 Jul 12;9:32. doi: 10.1186/1471-2466-9-32.

Braganza G, Chaudhuri R, McSharry C, et al. Effects of short-term treatment with atorvastatin in smokers with asthma--a randomized controlled trial. BMC Pulm Med. 2011 Apr 7;11:16. doi: 10.1186/1471-2466-11-16.

van Gestel YR, Hoeks SE, Sin DD, et al. Effect of statin therapy on mortality in patients with peripheral arterial disease and comparison of those with versus without associated chronic obstructive pulmonary disease. Am J Cardiol. 2008 Jul 15;102(2):192-6. doi: 10.1016/j.amjcard.2008.03.038.

El-Benna J, Dang PM, Périanin A. Towards specific NADPH oxidase inhibition by small synthetic peptides. Cell Mol Life Sci. 2012 Jul;69(14):2307-14. doi: 10.1007/s00018-012-1008-3.

Flora SJ. Structural, chemical and biological aspects of antioxidants for strategies against metal and metalloid exposure. Oxid Med Cell Longev. 2009 Sep-Oct;2(4):191-206. doi: 10.4161/oxim.2.4.9112.

Laleu B, Gaggini F, Orchard M, et al. First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis. J Med Chem. 2010 Nov 11;53(21):7715-30. doi: 10.1021/jm100773e.

Yao H, Edirisinghe I, Yang SR, et al. Genetic ablation of NADPH oxidase enhances susceptibility to cigarette smoke-induced lung inflammation and emphysema in mice. Am J Pathol. 2008 May;172(5):1222-37. doi: 10.2353/ajpath.2008.070765.

Golomb BA, Evans MA. Potential link between HMG-CoA reductase inhibitor (statin) use and interstitial lung disease. Med J Aust. 2007 Aug 20;187(4):253. PMID:17708735.

Hecker L, Cheng J, Thannickal VJ. Targeting NOX enzymes in pulmonary fibrosis. Cell Mol Life Sci. 2012 Jul;69(14):2365-71. doi: 10.1007/s00018-012-1012-7.

Hothersall E, McSharry C, Thomson NC. Potential therapeutic role for statins in respiratory disease. Thorax. 2006 Aug;61(8):729-34. doi: 10.1136/thx.2005.057976.

Stefanska J, Sarniak A, Wlodarczyk A, et al. Hydrogen peroxide and nitrite reduction in exhaled breath condensate of COPD patients. Pulm Pharmacol Ther. 2012 Oct;25(5):343-8. doi: 10.1016/j.pupt.2012.06.001.

Nadrous HF, Ryu JH, Douglas WW, Decker PA, Olson EJ. Impact of angiotensin-converting enzyme inhibitors and statins on survival in idiopathic pulmonary fibrosis. Chest. 2004 Aug;126(2):438-46. doi: 10.1378/chest.126.2.438.

Sutcliffe A, Hollins F, Gomez E, et al. Increased nicotinamide adenine dinucleotide phosphate oxidase 4 expression mediates intrinsic airway smooth muscle hypercontractility in asthma. Am J Respir Crit Care Med. 2012 Feb 1;185(3):267-74. doi: 10.1164/rccm.201107-1281OC.

Samson KT, Minoguchi K, Tanaka A, et al. Inhibitory effects of fluvastatin on cytokine and chemokine production by peripheral blood mononuclear cells in patients with allergic asthma. Clin Exp Allergy. 2006 Apr;36(4):475-82. doi: 10.1111/j.1365-2222.2006.02470.x.

Li J, Wang JJ, Yu Q, Chen K, Mahadev K, Zhang SX. Inhibition of reactive oxygen species by Lovastatin downregulates vascular endothelial growthfactor expression and ameliorates blood-retinal barrier breakdown in db/db mice: role of NADPH oxidase 4. Diabetes. 2010 Jun;59(6):1528-38. doi: 10.2337/db09-1057.

Kaparianos A, Argyropoulou E. Local renin-angiotensin II systems, angiotensin-converting enzyme and its homologue ACE2: their potential role in the pathogenesis of chronic obstructive pulmonary diseases, pulmonary hypertension and acute respiratory distress syndrome. Curr Med Chem. 2011;18(23):3506-15. PMID:21756232.

Katsuyama M, Matsuno K, Yabe-Nishimura C. Physiological roles of NOX/NADPH oxidase, the superoxide-generating enzyme. J Clin Biochem Nutr. 2012 Jan;50(1):9-22. doi: 10.3164/jcbn.11-06SR.

Kodgule R,Vaidya A, Salvi S. Newer therapies for chronic obstructive pulmona disease. J Assoc Physicians India. 2012 Feb;60 Suppl:8-13. PMID:23155806.

Kumar S. Free Radicals and Antioxidants: Human and Food System. Adv Appl Sci Res. 2011;2(1):129-135.

Ngkelo A, Meja K, Yeadon M, Adcock I, Kirkham PA. LPS induced inflammatory responses in human peripheral blood mononuclear cells is mediated through NOX4 and Giα dependent PI-3kinase signaling. J Inflamm (Lond). 2012 Jan 12;9(1):1. doi: 10.1186/1476-9255-9-1.

Mihos CG, Santana O. Pleiotropic effects of the HMG-CoA reductase inhibitors. Int J Gen Med. 2011 Apr 4;4:261-71. doi: 10.2147/IJGM.S16779.

Rey FE, Cifuentes ME, Kiarash A, Quinn MT, Pagano PJ. Novel competitive inhibitor of NAD(P)H oxidase assembly attenuates vascular O(2)(-) and systolic blood pressure in mice. Circ Res. 2001 Aug 31;89(5):408-14. PMID:11532901.

ten Freyhaus H, Huntgeburth M, Wingler K, et al. Novel Nox inhibitor VAS2870 attenuates PDGF-dependent smooth muscle cell chemotaxis, but not proliferation. Cardiovasc Res. 2006 Jul 15;71(2):331-41. doi:10.1016/j.cardiores.2006.01.022.

Wingler K, Hermans JJ, Schiffers P, Moens A, Paul M, Schmidt HH. NOX1, 2, 4, 5: counting out oxidative stress. Br J Pharmacol. 2011 Oct;164(3):866-83. doi: 10.1111/j.1476-5381.2011.01249.x.

Sun QA, Hess DT, Wang B, Miyagi M, Stamler JS. Off-target thiol alkylation by the NADPH oxidase inhibitor 3-benzyl-7-(2-benzoxazolyl)thio-1,2,3-triazolo[4,5-d]pyrimidine (VAS2870). Free Radic Biol Med. 2012 May 1;52(9):1897-902. doi: 10.1016/j.freeradbiomed.2012.02.046.

Pawlak J, Ziętkowski Z, Bodzenta-Łukaszyk A. Statins and asthma. Postepy Hig Med Dosw (Online). 2011 Mar 25;65:177-89. PMID:21502694.

Padhye S, Dandawate P, Yusufi M, Ahmad A, Sarkar FH. Perspectives on medicinal properties of plumbagin and its analogs. Med Res Rev. 2012 Nov;32(6):1131-58. doi: 10.1002/med.20235.

Biswas S, Hwang JW, Kirkham PA, Rahman I. Pharmacological and dietary antioxidant therapies for chronic obstructive pulmonary disease. Curr Med Chem. 2013;20(12):1496-530. PMID: 22963552.

Imamura M, Okunishi K, Ohtsu H, et al. Pravastatin attenuates allergic airway inflammation by suppressing antigen sensitisation, interleukin 17 production and antigen presentation in the lung. Thorax. 2009 Jan;64(1):44-9. doi: 10.1136/thx.2007.094540.

Shrikrishna D, Astin R, Kemp PR, Hopkinson NS. Renin-angiotensin system blockade: a novel therapeutic approach in chronic obstructive pulmonary disease. Clin Sci (Lond). 2012 Oct;123(8):487-98. doi: 10.1042/CS20120081.

Caldeira D , Alarcão J, Vaz-Carneiro A, Costa J. Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis. BMJ. 2012 Jul 11;345:e4260. doi: 10.1136/bmj.e4260.

Santana AN, Kairalla RA, Carvalho CR. Potential role of statin use in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008 May 1;177(9):1048. doi:10.1164/ajrccm.177.9.1048.

Takai S, Jin D, Ikeda H, Sakonjo H, Miyazaki M. Significance of angiotensin II receptor blockers with high affinity to angiotensin II type 1 receptors for vascular protection in rats. Hypertens Res. 2009 Oct;32(10):853-60. doi: 10.1038/hr.2009.116.

Borbély G, Szabadkai I, Horváth Z, et al. Small-molecule inhibitors of NADPH oxidase 4. J Med Chem. 2010 Sep 23;53(18):6758-62. doi: 10.1021/jm1004368.

Björkhem-Bergman L, Bergman P, Andersson J, Lindh JD. Statin treatment and mortality in bacterial infections--a systematic review and meta-analysis. PLoS One. 2010 May 19;5(5):e10702. doi: 10.1371/journal.pone.0010702.

Stanek E, Aubert R, Xia F, et al. Statin Exposure Reduces the Risk of Asthma-Related Hospitalizations and Emergency Room Visits in Asthmatic Patients on Inhaled Corticosteroids. J Allergy Clin Immunol. 2009 Feb;123(Suppl 2):S65. doi: 10.1016/j.jaci.2008.12.219.

Janda S, Park K, FitzGerald JM, Etminan M, Swiston J. Statins in COPD: a systematic review. Chest. 2009 Sep;136(3):734-743. doi: 10.1378/chest.09-0194.

Xu JF, Washko GR, Nakahira K, et al. Statins and pulmonary fibrosis: the potential role of NLRP3 inflammasome activation. Am J Respir Crit Care Med. 2012 Mar 1;185(5):547-56. doi: 10.1164/rccm.201108-1574OC.

Søyseth V, Brekke PH, Smith P, Omland T. Statin use is associated with reduced mortality in COPD. Eur Respir J. 2007 Feb;29(2):279-83. doi: 10.1183/09031936.00106406.

Jaulmes A, Sansilvestri-Morel P, Rolland-Valognes G, et al. Nox4 mediates the expression of plasminogen activator inhibitor-1 via p38 MAPK pathway in cultured human endothelial cells. Thromb Res. 2009 Sep;124(4):439-46. doi: 10.1016/j.thromres.2009.05.018.

Yuan C, Zhou L, Cheng J, et al. Statins as potential therapeutic drug for asthma? Respir Res. 2012 Nov 24;13:108. doi: 10.1186/1465-9921-13-108.

Xu L, Dong XW, Shen LL, et al. Simvastatin delivery via inhalation attenuates airway inflammation in a murine model of asthma. Int Immunopharmacol. 2012 Apr;12(4):556-64. doi: 10.1016/j.intimp.2012.01.012.

Solanes Garcia I, Casan Clarà P. Causes of death and prediction of mortality in COPD. Arch Bronconeumol. 2010 Jul;46(7):343-6. doi: 10.1016/j.arbres.2010.04.001. (in Spanish).

Schramm A, Matusik P, Osmenda G, Guzik TJ. Targeting NADPH oxidases in vascular pharmacology. Vascul Pharmacol. 2012 May-Jun;56(5-6):216-31. doi: 10.1016/j.vph.2012.02.012.

Sheng X, Murphy MJ, MacDonald TM, Wei L. The comparative effectiveness of statin therapy in selected chronic diseases compared with the remaining population. BMC Public Health. 2012 Aug 30;12:712. doi: 10.1186/1471-2458-12-712.

Mortensen EM, Restrepo MI, Anzueto A, Pugh J. The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia. Respir Res. 2005 Jul 25;6:82. DOI:10.1186/1465-9921-6-82.

Altenhöfer S, Kleikers PW, Radermacher KA, et al. The NOX toolbox: validating the role of NADPH oxidases in physiology and disease. Cell Mol Life Sci. 2012 Jul;69(14):2327-43. doi: 10.1007/s00018-012-1010-9.

Green DE, Murphy TC, Kang BY, et al. The Nox4 inhibitor GKT137831 attenuates hypoxia-induced pulmonary vascular cell proliferation. Am J Respir Cell Mol Biol. 2012 Nov;47(5):718-26. doi: 10.1165/rcmb.2011-0418OC.

Matera MG, Calzetta L, Rinaldi B, Cazzola M. Treatment of COPD: moving beyond the lungs. Curr Opin Pharmacol. 2012 Jun;12(3):315-22. doi: 10.1016/j.coph.2012.04.001.

Vinogradova Y, Coupland C, Hippisley-Cox J. Risk of pneumonia in patients taking statins: population-based nested case-control study. Br J Gen Pract. 2011 Nov;61(592):e742-8. doi: 10.3399/bjgp11X606654.

Williams HC, Griendling KK. NADPH oxidase inhibitors: new antihypertensive agents? J Cardiovasc Pharmacol. 2007 Jul;50(1):9-16. doi:10.1097/FJC.0b013e318063e820.

Young RP, Hopkins R, Eaton TE. Potential benefits of statins on morbidity and mortality in chronic obstructive pulmonary disease: a review of the evidence. Postgrad Med J. 2009 Aug;85(1006):414-21. doi: 10.1136/pgmj.2008.078477.

Copyright (c) 2018 CHILD`S HEALTH

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2020


   Seo анализ сайта